02 Advantages of AI in PharmaResearch – KML #machinelearning #CELLIMA #DrugDiscovery
AI Tools And Machine Learning In Pharmaceutical Research : A Dialogue with David Egan and Philipp Kainz
In a recent in-depth discussion on the CELLIMA TALKS @cellima-science podcast, David Egan, CEO of Core Life Analytics @corelifeanalytics164 , and Philipp Kainz, CEO of KML Vision @kmlvision explored the transformative impact of artificial intelligence (AI) and machine learning on early drug discovery. Here are some insights and predictions about the integration of these technologies into pharmaceutical research.
David Egan: “Bridging Biology and Data Science”
David Egan started his journey in molecular biology before moving into the niche of automating biological experiments, primarily in drug discovery. His move into data science was driven by the need to analyze complex data generated by automated processes. Today, his company, Core Life Analytics, focuses on developing software that enables biologists to harness machine learning for efficient drug discovery.
David explained: “Machine learning, or as it’s more commonly known, artificial intelligence, is now providing biologists with tools to speed up the drug discovery process.”
Philipp Kainz: “Histology and Image Analysis”
Philipp Kainz has a background in computer science and his work focuses on histological and high-content image analysis. He co-founded his company with Michael Mayrhofer-Reinhartshuber to address the challenges of handling large image data without coding expertise. His company now offers the IKOSA platform, a user-friendly service that allows users to train their own machine learning approach for individual image analysis applications. Philipp’s motivation is rooted in improving usability and reducing the stress associated with high content analysis.
Philipp explained: “Our vision is to improve the user experience so that biologists can work faster and more efficiently under increasing time pressure.”
Collaboration and Mutual Benefits
The collaboration between their companies is a strategic alliance aimed at integrating and leveraging their respective expertise in machine learning and image analysis. David and Philipp discussed how their partnership facilitates access to advanced technologies for their customers, enhancing both companies’ offerings to the pharmaceutical industry. David noted: “We are always looking for more advanced technologies to offer our customers, and partnering with Philipp’s company allows us to offer cutting-edge machine learning and image analysis capabilities.”
The collaboration between their companies is a strategic alliance aimed at integrating and leveraging their respective expertise in machine learning and image analysis. David and Philipp discussed how their partnership facilitates access to advanced technologies for their clients, enhancing both companies’ offerings to the pharmaceutical industry. David noted: “We’re always looking for more advanced technologies to provide to our customers, and partnering with Philipp’s company allows us to offer cutting-edge machine learning and image analysis capabilities.”
Challenges and Ethical Considerations
Despite the benefits, there are challenges to integrating AI into drug discovery, including data management, model validation and ethical concerns. Philipp highlighted the difficulties in ensuring model accuracy and the importance of building trust in AI systems. The dialogue also touched on the broader implications of AI in healthcare, particularly the ethical considerations and the potential for biased results if not carefully managed.
Looking Ahead
Looking to the future, both leaders were optimistic about the role of AI in improving pharmaceutical research. They expect advances in AI to streamline the drug discovery process, reduce costs and improve the accuracy and efficiency of pharmaceutical research. David concluded: “AI will revolutionize the way we discover and develop new drugs, significantly speeding up the process and improving outcomes.”
Bottom Line
This enlightening conversation with David and Philipp not only sheds light on the current applications of AI and machine learning in drug discovery to analyze large amounts of data, particularly from high-content imaging, but also explores the potential future developments in the field. Their insights are invaluable for anyone interested in the intersection of technology and healthcare, and offer a glimpse into the future of medical research enabled by artificial intelligence.
source
